Drug Profile
MEDI 3726
Alternative Names: ADCT 401; MEDI-3726Latest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator ADC Therapeutics
- Developer ADC Therapeutics; MedImmune
- Class Antineoplastics; Benzodiazepines; Drug conjugates; Immunoconjugates; Monoclonal antibodies; Pyrroles
- Mechanism of Action DNA cross linking agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Prostate cancer
Most Recent Events
- 30 Sep 2019 MedImmune completes a phase I trial in Prostate cancer (Metastatic disease; Second line therapy or greater) in USA (Parenteral) (NCT02991911)
- 25 Jul 2019 Discontinued - Phase-I for Prostate cancer (Metastatic disease, Second-line therapy or greater) in USA (Parenteral) before July 2019 due to safety and efficacy issues (NCT02264678) (Astrazeneca pipeline, July 2019)
- 15 Aug 2018 MedImmune re-initiates phase I trial in Prostate cancer (Metastatic disease; Second line therapy or greater) in USA (NCT02991911)